Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Aprea Therapeutics

12/08/2026 14:24

Aprea Therapeutics Inc APRE.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -53 cents.  The mean expectation of four analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from -25 cents to -22 cents per share.
Reported revenue was zero​; analysts expected $168.67 thousand. 
Aprea Therapeutics Inc's reported EPS for the quarter was a loss of 7 cents​.
The company reported a quarterly loss of $3.59 million.
Aprea Therapeutics Inc shares had fallen by 17.7% this quarter and lost 22.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Aprea Therapeutics Inc is $5.00, about 86.8% above its last closing price of $0.66
This summary was machine generated from LSEG data August 12 at 01:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.23
-0.07
Beat
Mar. 31 2026 
-0.23
-0.22
Beat
Dec. 31 2025 
-0.39
-0.32
Beat
Sep. 30 2025 
-0.34
-0.47
Missed